The Horizon Platform
01 - The Platform
Providing clinicians critical visibility into tumor biology
CellaraRx’s Horizon platform enables clinicians and drug developers to identify which patients are most likely to respond to cancer treatments in clinical trials - before enrollment begins.
By combining single-cell RNA sequencing, digital pathology, and AI, Horizon reveals tumor features that standard methods cannot detect.
02 - How Horizon Works
01
Inputs
Pre-enrollment, Horizon integrates multiple biological data sources:
✔ Single-cell RNA sequencing
✔ Digital pathology imaging
✔ Multi-omics tumor data
This enables analysis of tumors at the level of individual cells and their spatial organization within tissue.
02
Visibility
Horizon identifies insights often invisible to standard genomic approaches:
✔ Which cancer cells may already be resistant to a therapy
✔ Where those cells are located within the tumor
✔ Whether the drug can effectively reach its intended targets
These insights determine whether a patient’s tumor is biologically compatibile with a therapy.
03
Outcomes
By identifying resistance mechanisms and tissue accessibility pre-enrollment, Horizon ensures:
✔ More precise patient stratification for clinical trials
✔ Improved trial design and success rates
✔ Reduced late-stage trial failures
This results in the right patients receiving the right therapies.